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INTRODUCTION 
A high level of case ascertainment by cancer registries is essential to allow estimation of accurate 
incidence rates and survival. Nearly 20 years ago, researchers assessed the completeness and 
accuracy of registration of primary intracranial tumours in the Scottish Cancer Registry (SCR)1 
compared to a database assembled in the context of a detailed incidence study carried out in the 
Lothian region of Scotland covering the period of diagnosis, 1989-19901-2.  Disappointingly, SCR 
identified only 54% of cases, although the registry at that time did not attempt to collect information 
on ‘benign’ intracranial neoplasms which were included in the detailed incidence study.  Even so, 
only 84% of neuro-epithelial tumours were identified by SCR, probably related in part to the fact 
that, the cancer registry was not receiving neuropathology data from the regional neuro-oncology 
centre.  An English study reported similar findings with only 52% of cases appearing in the regional 
cancer registry3. 
Over time, access to diagnostic techniques has improved alongside improvements and changes in 
classification and clinical coding. Furthermore, SCR now receives neuropathology data from all 
neuro-oncology centres in Scotland, and has sought to collect information on benign tumours of the 
brain and spinal cord since the year of diagnosis, 2000. In light of these developments, we aimed to 
determine the completeness of ascertainment of primary intracranial tumours by SCR through 
independent/clinical case ascertainment in NHS Lothian for the period of diagnosis, 2011-2012. 
 
                                                          
1
 ICD-O-3 International Classification of Diseases for Oncology; MDTM multidisciplinary team meeting; National 
Records Scotland; SCR Scottish Cancer Registry; SMR01 Scottish Morbidity Record 01; SNOMED Systematized 
Nomenclature of Medicine. 
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METHODS 
Scottish Cancer Registry (SCR) 
SCR operates by bringing together predominantly electronic information from: hospital patient 
administration systems including patient discharges from hospital (SMR01), radiotherapy, oncology, 
pathology records; death records from National Records Scotland (NRS); and private hospital 
records4. All primary malignant and benign brain tumours are recorded on the SCR. 
Inclusion and exclusion criteria 
This retrospective cohort study was restricted to the period of diagnosis between 1/1/11 and 
31/12/12 and limited to adults (age ≥18years on the date of diagnosis) with a postcode within the 
NHS Lothian health board region (mid-year population ~650,000). The date of diagnosis was taken as 
i) the date of the first abnormal imaging, or ii) the date of biopsy/resection. Patients in whom there 
was no neuro-radiology or histology were excluded, i.e. diagnosis of prolactinoma had to be 
supported by blood tests and imaging. 
All suspected and histologically proven primary intracranial tumours (benign and malignant) of the 
brain and cranial nerves were counted, including primary central nervous system lymphoma. 
Meningeal, pituitary region and pituitary gland tumours were also included. Cerebral metastases, 
tumours of the spinal cord and spinal nerves, and recurrent intracranial tumours of any type were 
excluded.  
Extraction from the SCR 
Data were extracted for the study period for all records including the following anatomical site codes 
selected from the third edition of the International Classification of Diseases for Oncology (ICD-O-3): 
C70.0, C70.9, C71, C72.2, C72.3, C72.4, C72.5, C72.8, C72.9, C75.1, C75.2, and C75.3 (all behaviour 
codes). 
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Clinical case ascertainment   
Three clinical sources were trawled: i) neuro-oncology multidisciplinary meeting minutes (MTDM); ii) 
an endocrinology database; and iii) neuropathology records (sources i and ii are independent of the 
SCR data collection system).  The neuro-oncology MDTM aims to discuss all intracranial tumours 
identified via any means including both benign and malignant tumours. The endocrinology database 
records all patients attending the endocrine outpatient clinics in the NHS Lothian region and each is 
assigned a diagnosis by a Consultant Endocrinologist. Both sources i and ii for the period 1 Jan 2011 
to 31 March 2013 were reviewed manually by JRM. The neuropathology records hold information on 
all tissue samples analysed in the pathology system for NHS Lothian hospitals and an electronic 
extract was obtained using Systematized Nomenclature of Medicine (SNOMED) codes matching 
those above. To ensure cases were true incident cases meeting the full inclusion criteria, each was 
cross referenced with the patient’s electronic secondary care medical record. 
Analysis 
Clinically ascertained cases were reconciled against the SCR extract. We have previously quantified 
the extent of misclassification of incidence year in the Scottish Cancer Registration database5. We 
did not regard misclassifications of incidence year as missed or ‘over-diagnosed’ cases as there is no 
reason to believe that such misclassification is other than random. 
Completeness was defined as the proportion of intracranial tumours included in the SCR out of all 
those identified as diagnosed in residents of NHS Lothian area during the study period.  Confidence 
intervals (95%) for completeness were calculated using the exact method. 
Completeness was calculated for all intracranial tumours with secondary analysis of completeness by 
tumour morphology and tumour grade (see Supplementary File for coding definitions). 
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Ethical approval 
The study was considered health-service audit and did not require NHS ethical review as the project 
was limited to the utilisation of data previously collected in the course of normal care. NHS Lothian 
Caldicott Guardian approval was obtained for the use of person-identifiable information. 
 
RESULTS 
There were 320 records of primary intracranial tumours registered on the SCR for the period of 
interest and 264 clinical cases were ascertained.  Figure 1 shows the final ascertainment of clinical 
cases missing from the SCR.  
42 clinical cases were identified as missing from the SCR, with 98 cases on the SCR not identified by 
searching clinical sources. The 42 missing cases were identified from: neuro-oncology MDTM (7), 
endocrinology out-patient database (30) and neuropathology records (5).  
Overall case ascertainment was 88.4%, which after exclusion of pituitary adenomas (22.6% macro- 
and 77.4% micro-adenomas) rose to 96.3%  
Table 1 shows the ascertainment by tumour morphology. All tumour types had ascertainment >90% 
with the exception of pituitary adenomas (53.7%) and unidentifiable tumours (77.8%). Considering 
tumours by grade (with pituitary adenomas removed due to poor acquisition), missing cases were 
most prominent in the high grade (IV) tumours, with 4.8% of cases missing.  
Of the 98 cases on the SCR not identified in the clinical case ascertainment the reasons for non-
ascertainment were: 7 (7.1%) died within 1-month of the diagnosis or were registered from death 
certification/autopsy, 9 (9.2%) had a diagnostic date recorded in their medical records outside of the 
period 2011-12, 79 (80.6%) were confirmed as accurate registrations from their medical records but 
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were not referred to the neuro-oncology MDTM or had pathology specimens taken, and 3 (3.1%) 
were diagnosed and/or treated outside of the NHS Lothian region. 
The morphology of these 98 were: 9 (9.2%) neuroepithelial, 19 (19.4%) cranial nerve, 49 (50.0%) 
meningeal, 1 (1.0%) primary CNS lymphoma, 11 (11.2%) pituitary adenomas, and 9 (9.2%) unknown. 
 
DISCUSSION 
This study found the SCR to be near complete (96.3%) for non-pituitary intracranial tumours. This 
finding is reassuring given the increasing reliance on routine data sources in clinical research in the 
‘big data’ era.  
A key strength of this work was the use of predominantly independent clinical case ascertainment. 
Two of the three sources used were independent of the SCR with the pathology database part of the 
routine reporting system. Use of dependent sources would lean to an over-estimation of the 
completeness, however, we are confident in our finding as the search employed for the pathology 
extract was more extensive than the SCR compiling extract and we did identify further missing cases. 
To further augment the clinical case ascertainment imaging sources could also be used. 
Unfortunately it was not possible for us to do this due to the very high volume of imaging activity 
and the fact that report findings are not synoptic or coded.  
 Another possible weakness was the use of a single researcher (JRM) in identifying independent 
cases. To try and minimise missing cases or misclassification, all missing cases had the medical 
records rechecked by the researcher and a member of the SCR data quality assurance team 
reviewed the registry for the entry, outside of the extract requested.  
This work replaces prior completeness estimates published in the late 1990’s1 and shows a clear 
improvement in the completeness of ascertainment. This is likely to relate to operational changes in 
the way that data are collected by SCR and the decision to collect data on benign brain tumours 
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from year 2000 onwards. It is possible that completeness of ascertainment of tumours varies by site 
with other cancers potentially having higher completeness, however these findings are more 
consistent with estimates of completeness of ascertainment for other cancer sites/types in SCR6-7. 
It is important that outdated estimations of completeness of ascertainment of intracranial tumours 
are revised to ensure robust estimates of intracranial tumour incidence are made and understood. 
The use of outdated information can lead to misleading inferences, for example, The Brain Tumour 
Charity continues to report a belief that "many brain tumours are not recorded" in official statistics 
in Scotland8.  
Conclusion 
Given the increase in intracranial tumours being diagnosed by imaging we would recommend a 
move towards diagnostic coding of imaging in Scotland. A further issue to address in the future 
relates to the recording of benign pituitary tumours – predominantly microadenomas. We found 
that most of these were noted in the records of out-patient endocrinology attendances following 
CT/MRI scanning. It is unclear how a national system to collect these could be implemented because, 
at present, diagnosis is not coded in either computerised imaging data or outpatient data collected 
routinely.   
[words 1538] 
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TABLES AND FIGURES 
Figure 1 Flowchart of ascertainment of cases missing from the Scottish Cancer Registry (SCR). 
 
SCR Scottish Cancer Registry 
 
Reconciliation 
Cases on the SCR 
n=320 
Independent case 
ascertainment 
n=264 
Confirmed ascertained 
cases not on SCR 
n=42 
Cases on SCR not identified by 
independent case ascertainment 
n=98 
Matching cases 
n=222 
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Table 1 Completeness of primary intracranial tumour recording on the Scottish Cancer Registry 
(SCR) for NHS Lothian by tumour morphology 
Tumour morphology 
Number on 
SCR [a] 
Additional 
‘clinical’ cases 
[b] 
Case ascertainment,  
% (95%CI) [a/a+b] 
Crude incidence (≥18 
years) per 100,000 
person-years 
Neuroepithelial 134 5 96.4  
(91.4, 98.7) 
10.6 
Cranial nerves 22 1 95.7  
(76.0, 99.8) 
1.8 
Tumours of the meninges 105 1 99.1  
(94.1, 100) 
8.1 
Lymphomas and 
haemopoetic 
7 0 100  
(56.1, 100) 
0.5 
Germ cell 0 0 - - 
Sellar region 2 0 100  
(19.8, 100) 
0.2 
Pituitary 
adenoma/prolactinoma 
36 31 53.7  
(41.2, 65.8) 
4.9 
Unknown 14 4 77.8  
(51.9, 92.6) 
1.4 
Total 
     
 Excluding pituitary tumours 
320 
 
284 
42 
 
11 
88.4  
(84.5, 91.4) 
96.3 
 (93.2-98.0) 
27.6 
 
22.5 
 
 
